In the era of precision medicine, the employment of appropriate targeted therapies according to individualized tumor signatures have emerged as an attractive therapeutic approach.42,43 Based on previous studies that MVC improves the efficacy of DNA damage agents,28,44 we proposed a therapeutic strategy of combining CCL5-CCR5 targeting agents such as MVC with TMZ to improve chemotherapeutic efficacy. The gene discussed is CCR5; the disease is neoplasm.